In their review, the authors compiled preclinical and clinical evidence showing that platelet release of their granule contents, including VEGF, platelet derived growth factor (PDGF), fibroblast growth factor-2 (FGF-2), and matrix metalloproteases (MMPs) increases angiogenesis by at least 25%, which in turn increases the proliferation, migration, and invasiveness, and reduces the cisplatin sensitivity, of tumor cells. This evidence concerns the gene FGF2 and neoplasm.